melanocortin comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-05-06. Numbers and descriptions here follow the published literature rather than marketing material.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Compared with melanotan II, bremelanotide is a smaller cyclic peptide with a more constrained backbone, which affects receptor selectivity and metabolic stability. Published descriptions give a plasma half-life on the order of a few hours after subcutaneous administration, with elimination through hepatic and renal routes and limited plasma protein binding. Central access is inferred from effects observed in animal models, although direct measurement in humans is limited. Handling and storage requirements follow from the peptide backbone, which is susceptible to hydrolysis and oxidation.
The melanocortin system comprises five G protein-coupled receptors, designated MC1 through MC5, that signal mainly through cyclic AMP accumulation. MC1R and MC2R are associated with pigmentation and adrenal steroid production, while MC3R and MC4R are expressed in the central nervous system and influence energy balance and behavior. MC5R appears in exocrine tissues. Natural agonists include alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone, and endogenous antagonists such as agouti-related protein modulate the same sites. This receptor family provides the framework within which bremelanotide activity is described.
| Property | Value | Notes |
|---|---|---|
| Research code | PT-141 | Used in early literature before the generic name became common |
| Generic name | Bremelanotide | International nonproprietary name |
| Peptide class | Cyclic heptapeptide | Seven residues joined by a lactam bridge |
| Primary receptor | MC4R | Lower affinity reported at MC1R, MC3R and MC5R |
| Route studied clinically | Subcutaneous injection | Intranasal route was abandoned after pressor effects |
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.
Across literature and commercial listings, the substance appears under several names, including bremelanotide, PT-141, and various brand designations. A CAS registry number provides a unique identifier for the compound, aiding retrieval from chemical databases. Synonym lists may also contain early development codes and descriptive chemical names. When consulting sources, researchers need to confirm that the cited names refer to the same molecular structure to avoid confusion. Naming consistency matters especially when comparing analytical data across publications.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
October 8 – The US begins direct negotiations with the military junta while continuing sanctions against its leader, Min Aung Hlaing, for human rights violations, notably the Rohingya genocide. The Pentagon instructs the US Central Command to get ready in case direct military operations against Iran were to resume. U.S. and Israeli officials suggests that joint strikes against Iranian nuclear, energy, and infrastructure sites might take place prior to either the November US midterm elections or the late October Israeli general election, even though Trump had not made a final decision or established a timeline. Internal assessments and energy analysts cautions that renewed hostilities would fail to lower immediate gasoline prices and could instead cause a sharp spike in global oil prices, despite the administration's goal of a military breakthrough to eventually lower domestic fuel costs. Further sanctions are put by the US on Iran's shadow fleet.
Berg did not complete his final step due to the pleas of several fellow investigators, including Robert Pollack, who feared the biohazards associated with the last step. The SV40 was known to cause cancer tumors to develop in mice. Additionally, the E. coli bacterium (although not the strain used by Berg) inhabited the human intestinal tract. For these reasons, the other investigators feared that the final step would create cloned SV40 DNA that might escape into the environment and infect laboratory workers. These workers could then become cancer victims. Concern about this potential biohazard, along with others, caused a group of leading researchers to send a letter to the president of the National Academy of Sciences (NAS). In this letter, they requested that he appoint an ad hoc committee to study the bio-safety ramifications of this new technology. This committee, called the Committee on Recombinant DNA molecules of the National Academy of Science, U.S.A., held in 1974, concluded that an international conference was necessary to resolve the issue and that until that time, scientists should halt experiments involving recombinant DNA technology.
This synthesis reaction was used by Fermi and his collaborators in their design of the reactors located at the Hanford Site, which produced significant amounts of plutonium-239 for the nuclear weapons of the Manhattan Project and the United States' post-war nuclear arsenal. Actinides with the highest mass numbers are synthesized by bombarding uranium, plutonium, curium and californium with ions of nitrogen, oxygen, carbon, neon or boron in a particle accelerator. Thus nobelium was produced by bombarding uranium-238 with neon-22 as
Glibenclamide, also known as glyburide (U.S. English), is an antidiabetic medication used to treat type 2 diabetes. It is recommended that it be taken together with diet and exercise. It may be used with other antidiabetic medication. It is not recommended for use by itself in type 1 diabetes. It is taken by mouth. Common side effects include nausea and heartburn. Serious side effects may include angioedema and low blood sugar. It is generally not recommended during pregnancy but can be used during breastfeeding. It is in the sulfonylureas class of medications and works by increasing the release of insulin from the pancreas. Glibenclamide was discovered in 1969 and approved for medical use in the United States in 1984. It is available as a generic medication. In 2021, it was the 214th most commonly prescribed medication in the United States, with more than 2 million prescriptions.
=== 13-31 August 2008 === An anonymous U.S. functionary said: "Saakashvili had always told us he could not stand by while Georgian villages were being shelled, and we always knew this was a point of pressure. We always told him that he should not give in to the kind of provocations we knew the Russians were capable of." In August 2008, Modest Kolerov, former head of the Department for international and cultural ties with foreign countries of the President's Office, admitted that the Kremlin had "a clear plan of action in the case of a conflict", and "the expediency with which the military operation was executed confirms that." Robert Gates, United States Secretary of Defense, said on August 14 that there had been clashes with the South Ossetian forces each August since 2004, but "This year it escalated very quickly and it seemed to me that Russians were prepared to take advantage of an opportunity and did so very aggressively." Zbigniew Brzezinski compared Russia's attack on Georgia to the Soviet attack on Finland and wrote that "Moscow was waiting for such an act to provide a pretext for the use of force." He suggested that Russia could attack Ukraine and other post-Soviet countries were not safe. Ralph Peters, a former military intelligence analyst, and several western diplomats (a western diplomat with contacts with the Georgians and a western mediator acquainted with Saakashvili) said that it was Russia who was provoking Georgia. It was reported that the United States had prevented Saakashvili from taking military action in Abkhazia in early May 2008.
Sources: en.wikipedia.org
====== Master's degree and Graduate Certificate Programs in Pharmacy Leadership ====== In 2016, the college became the first pharmacy school in the US to offer an online MS degree program and graduate certificate in pharmacy leadership. These programs combine leadership and professional development in health care business and management courses. These are the first programs at the university to be a partnership between three difference colleges:
=== Side effects === Nicomorphine's side effects are similar to those of other opioids and include itching, nausea and respiratory depression. It is considered by doctors to be one of the better analgesics for the comprehensive mitigation of suffering, as opposed to purely clouding the noxious pain stimulus, in the alleviation of chronic pain conditions.
SDA, also known as 3,4-methylenethiooxyamphetamine (3T-MDA), is a putative entactogen and psychedelic drug of the phenethylamine and amphetamine families related to 3,4-methylenedioxyamphetamine (MDA). It is the analogue of MDA in which the oxygen atom at the 3 position within the 3,4-methylenedioxy substitution has been replaced with a sulfur atom to give a 1,3-benzoxathiole rather than 1,3-benzodioxole ring system. The drug is also the N-desmethyl analogue of 3,4-methylenethiooxy-N-methylamphetamine (SDMA; 3T-MDMA).
TAN-821 is an opioid drug which was originally reported as an agonist for the putative ε-opioid receptor, however this is now thought not to be a separate opioid receptor in its own right but is more likely a heteromer made from hybridisation of known opioid receptor subunits. It has subsequently been shown to have potent affinity for the kappa opioid receptor.
Sources: en.wikipedia.org
=== Interactions === Lorazepam is not usually fatal in overdose but may cause respiratory depression if taken in overdose with alcohol. The combination also causes greater enhancement of the disinhibitory and amnesic effects of both drugs, with potentially embarrassing or criminal consequences. Some experts advise that people should be warned against drinking alcohol while on lorazepam treatment, but such clear warnings are not universal. Greater adverse effects may also occur when lorazepam is used with other drugs, such as opioids or other hypnotics. Lorazepam may also interact with rifabutin. Valproate inhibits the metabolism of lorazepam, whereas carbamazepine, lamotrigine, phenobarbital, phenytoin, and rifampin increase its rate of metabolism. Some antidepressants, antiepileptic drugs such as phenobarbital, phenytoin, and carbamazepine, sedative antihistamines, opiates, antipsychotics, and alcohol, when taken with lorazepam may result in enhanced sedative effects.
==== Urquía Carreño resigns ==== On August 18, 2024, a special session of more than a hundred Freemasons was called by Urquía Carreño to gather at the theatre hall of the Grand Lodge of Cuba, on the 3rd floor of the building. One Cuban Freemason told reporters that: "...he had manipulated a circus to stay in office. He's shameless, they were lies after lies; all the brothers were standing asking him to hand over the keys to his office." The people in the theatre started chanting: "Hand over and leave!" After tensions had escalated, Urquía Carreño left the theatre to go back to his office. However, the Freemasons followed him up to the eleventh floor. Urquía Carreño agreed to meet with representatives of the delegation in his office, so three men were chosen to represent them. The three men sat with three of Urquía Carreño's men, and discussed terms of negotiation, while the rest of the delegation waited in the hallway. On August 18, 2024, after two hours of negotiation, Urquía Carreño finally relented and agreed to tender his resignation. In his resignation, he said that it was: "for the good of the institution." Mayker Filema Duarte assumed the role of Acting Grand Master until an election could be held, and immediately launched a financial audit of the entire Grand Lodge. At the beginning of September, Filema Duarte accused Urquía Carreño of the theft of yet another $MN2,116,555.33, stolen sometime between January and August 2024.
=== Elderly === Skin ageing is associated with increased skin vulnerability, and the texture and colour of the skin can change over time. Although wrinkles occur naturally due to ageing, smoking can intensify the appearance of wrinkles. Sunspots, dryness, wrinkles, and melanomas can occur from UV exposure over time, whether it be through the sun or through tanning beds. Exposure to UV can make skin less elastic. Skin problems including pruritus are common in the elderly but are often inadequately addressed. A literature review of studies assessing the maintenance of skin integrity in the elderly found most studies to have low levels of evidence, but the review concluded that skin-cleansing with synthetic detergents or amphoteric surfactants induced less skin dryness than using soap and water. Moisturizers with humectants helped with skin dryness and skin barrier occlusive reduced skin injuries. When taking baths or showers, using warm water rather than hot water can aid with dryness.
While a number of wholesale markets observed the shutdown, the newspaper claimed a majority of kirana stores and neighborhood small shops – for whom apparently the trade bandh had been called – remained open, ignoring the shutdown call. Conflicting claims were made by the organisers of the nationwide shutdown. Contrary to eyewitness reports, one Trader union's secretary general claimed traders across the country participated wholeheartedly in the strike. The political parties opposing the retail reforms physically disrupted and forced India's parliament to adjourn again on Friday 2 December 2011. The Indian government refused to cave in, in its attempt to convince through dialogue that retail reforms are necessary to protect the farmers and consumers. Indian parliament has been dysfunctional for the entire week of 28 November 2011 over the opposition to retail reforms.
== Anthocyanins == Anthocyanins define the blue pigmentation of açaí and the antioxidant capacity of the plant's natural defense mechanisms and in laboratory experiments in vitro. Anthocyanins in açaí accounted for only about 10% of the overall antioxidant capacity in vitro. The Linus Pauling Institute and European Food Safety Authority state that "the relative contribution of dietary flavonoids to (...) antioxidant function in vivo is likely to be very small or negligible". Unlike in controlled test tube conditions, anthocyanins have been shown to be poorly conserved (less than 5%) in vivo, and most of what is absorbed exists as chemically modified metabolites destined for rapid excretion. A powdered preparation of freeze-dried açaí fruit pulp and skin was shown to contain cyanidin 3-O-glucoside and cyanidin 3-O-rutinoside as major anthocyanins (3.19 mg/g). The powdered preparation was also reported to contain twelve flavonoid-like compounds, including homoorientin, orientin, taxifolin deoxyhexose, isovitexin, scoparin, as well as proanthocyanidins (12.89 mg/g), and low levels of resveratrol (1.1 μg/g).
Sources: en.wikipedia.org
The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.
MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.
Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.
Reported activity is highest at MC4R, with lower potency at MC1R and MC3R. The MC4R interaction is generally treated as the most relevant to its central effects. Selectivity is not absolute, and activity across the family is dose-dependent.